Immunogene therapy for glioblastoma
- Prosjektnummer
- 912044
- Ansvarlig person
- Hrvoje Miletic
- Institusjon
- Helse Bergen HF
- Prosjektkategori
- Åpen prosjektstøtte
- Helsekategori
- Cancer, Neurological
- Forskningsaktivitet
- 5. Treatment Developement
The goal of the project is to establish a new immunogene therapy. We are about to validate interesting cytokine candidates together with the suicide gene therapy experimentally. We have filled out a DOFI about this new therapy and sent it to BTO. At this stage "brukermedvirkning" is not relevant, but might become relevant when/if we enter the clinical phase of development. There is still a long way to go as we first need to verify combination therapy experimentally. When/If the patent is filed, we can start to attract investors in order to be able to move to clinical translation of the product.
Long-term treatment with valganciclovir improves lentiviral suicide gene therapy of glioblastoma.
Neuro Oncol 2019 Jul 11;21(7):890-900.
PMID: 30958558
Cancer Suicide Gene Therapy with TK.007.
Methods Mol Biol 2019;1895():11-26.
PMID: 30539526
- Abdul Latif Ph.d.-kandidat
- Romi Roy Choudhury Ph.d.-kandidat
- Sandra Ninzima Prosjektdeltaker
- Jubayer Hossain Postdoktor
- Hrvoje Miletic Prosjektleder
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til Faglig rapportering, Helse Vest